Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-25-107127
Filing Date
2025-04-30
Accepted
2025-04-30 16:05:19
Documents
20
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d920870d10ka.htm   iXBRL 10-K/A 355386
2 EX-10.11 d920870dex1011.htm EX-10.11 39441
3 EX-10.12 d920870dex1012.htm EX-10.12 37566
4 EX-31.3 d920870dex313.htm EX-31.3 4182
5 EX-31.4 d920870dex314.htm EX-31.4 4208
  Complete submission text file 0001193125-25-107127.txt   838011

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tpst-20241231.xsd EX-101.SCH 5615
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20241231_def.xml EX-101.DEF 20805
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20241231_lab.xml EX-101.LAB 26293
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20241231_pre.xml EX-101.PRE 21890
23 EXTRACTED XBRL INSTANCE DOCUMENT d920870d10ka_htm.xml XML 11620
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-35890 | Film No.: 25894908
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)